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INTRODUCTION
In developing countries, carcinoma of the cervix is an im  por­
tant cause of cancer­related death in women [1,2]. The 5­year 
overall survival rate depends mainly on tumour stage [1,3­5]. 
and varies from 98% in early stage disease to 10% in the most 
advanced stages [5]. In the last decade, outcome has im  proved 
due to the development of new treatment stra  tegies such as 
the addition of chemotherapy to radiation [6­8]. 
Currently, a number of treatment options for patients with 
cervical cancer are available, including surgery, radiotherapy, 
chemotherapy and hyperthermia, either as single or as com­
bined modality, and the choice of treatment aims at achieving 
the best results with the least morbidity [5,9,10]. 
Until 1999, the primary treatment for locally advanced cervi­
cal carcinoma was radiotherapy, where the tolerance of nor­
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Objective: Concurrent chemoradiation has improved survival of patients with cervical carcinoma. However, follow­up of 
randomized studies is relatively short and data on long term toxicity are scarce, as is information on their health­related 
quality of life. This study assesses and compares incidences of late side­effects among patients treated with radiotherapy or 
chemoradiation using two toxicity scoring systems, and investigates impact on health­related quality of life.
Methods: Between 1985 and 1993, 114 patients underwent radiotherapy (n=39) or chemoradiation (n=75) for stage IIA­IVB 
cervical carcinoma. Late side­effects were scored retrospectively by reviewing medical charts using standardised checklists, 
focusing on bladder­ and intestinal side effects. Health­related quality of life was assessed once using the EORTC QLQ­C30.
Results: No significant differences in late treatment­related side­effects between radiotherapy and chemoradiation groups 
were found. Grade ≥ 2 toxicity was found in 33% (bladder), and in 6% (bowel). Only 1.8% had both grade 3­4 toxicity. Bladder 
syndrome with high urinary frequency, urine incontinence and small bowel toxicity had a significant impact on health­related 
quality of life.
Conclusion: Grade 2 are relatively frequent late side effects in curatively treated patients, but are not enhanced by the addition 
of chemotherapy. Their negative impact on health­related quality of life stresses the importance of new radiation techniques, 
aiming at reduction of these side effects.
Keywords: Cervical carcinoma, Concurrent radiochemotherapy, Late treatment­related morbidity, Radiotherapy
J Gynecol Oncol Vol. 22, No. 3:152-160
http://dx.doi.org/10.3802/jgo.2011.22.3.152Treatment-related morbidity and QoL in cervical carcinoma
J Gynecol Oncol Vol. 22, No. 3:152-160 www.ejgo.org 153
mal tissues limits the dose intensity [5,11]. Recently, the results 
of a number of clinical phase III studies have shown that add­
ing cisplatin­based chemotherapy provides higher cure rates 
than radiotherapy alone [12­15] Therefore, in patients with 
stage IIB and higher, concurrent chemoradiation is now con­
sidered standard treatment [1,3,16,17]. As a result, the number 
of surviving patients has increased as well as the prevalence 
of women suffering from late radiation­induced side effects 
[1,17]. It could be hypothesized that the addition of chemo­
therapy to radiation has increased the risk of late side effects. 
However, as the follow­up of most randomized studies still 
is relatively short, reliable data regarding late side effects are 
scarce. 
A number of scoring systems for late treatment related side 
effects exist, of which the Common Terminology Criteria for 
Adverse Events version 3.0 (CTCAE v3.0) and ‘The late mor  bidi­
ty scoring scheme’ from Radiation Therapy Oncology Group/
European Organization for Research and Treatment of Cancer 
(RTOG/EORTC), are the most frequently used [1,11,12,18­25]. 
In the RTOG/EORTC scoring system, the number of toxicity scales 
related to side effects of the gastrointestinal and urinary tract 
is limited as compared to the CTCAE v3.0 scoring system, 
which enables a more precise definition of these side effects. 
The difference between these scoring systems may have con­
se  quences for the reporting of late side effects among vari  ous 
studies. Determination of the precise incidence and pre  valence 
of radiation­induced side effects requires a direct com  parison 
between these two systems in the same study co  hort. It might 
be assumed that the grading of late side effects may be related 
to the health­related quality of life scores (HRQoL). However, 
this assumption has never been studied among patients cura­
tively treated for cervical cancer. 
Therefore, the purposes of this study were: 1) to assess the 
in  ci  dence of late radiation­induced side effects among pa­
tients curatively treated with radiotherapy with or without che­
mo  therapy; 2) to assess whether the addition of con  current 
chemotherapy resulted in higher rates of late radiation­indu­
ced side effects; 3) to investigate the association between late 
treatment­related side effects and HRQoL scored with the 
men  tioned scoring systems. 
MATERIALS AND METHODS
1. Patients
The population of this retrospective cohort study was 
composed of 114 patients who were treated primarily with 
curative intent for locally advanced cervical carcinoma at the 
University Medical Centre of Groningen (UMCG) in the period 
from 1985 to 1993. Thirty­nine patients (34%) received cura­
tive radiotherapy (RT) alone from 1986­1989, while 75 patients 
(66%) received concurrent chemoradiation (CRT) from 1989­
1993 in a phase II study [26]. 
For pre­treatment tumour staging, physical examination un­
der general anesthesia was performed by the gynecologic on­
cologist together with the radiation­oncologist. Tumour stag­
ing was performed according to the International Federation 
of Gynecology and Obstetrics (FIGO)­classification system. A 
chest X­ray or computed tomography (CT) scan of the thorax 
was performed in all patients as well as a pelvic and abdomi­
nal CT scan to assess lymph node status. Ultrasound of the 
urinary tract, cystoscopy, and/or proctoscopy was only per­
formed when clinically indicated. Some patients underwent a 
lymphangiography to assess lymph node involvement. 
2. Treatment
Radiotherapy: Radiation therapy was delivered by a 6 mega­
volt (MeV) photon linear accelerator in a standard protocol 
[27]. In general, a “box” technique was used, including an 
anterior, posterior and two lateral opposing fields with direct 
simulation. The superior limit of the anterior­posterior fields 
was the upper border of the fourth lumbar vertebra. The 
lower limit was the lower margin of the obturator foramen 
(or, in stage IIIA, the distal vagina). The lateral margin was 2 
cm lateral from the transverse diameter of the pelvic brim. For 
the lateral fields, the ventral limit was the upper margin of the 
symphysis and the dorsal limit was the front of the sacrum. 
Radiation was given by 1.8 Gy daily fractions, five times per 
week to a total dose of 45 Gy.
Two weeks after completing external beam irradiation, a 
second examination under general anesthesia was performed 
and, if technically feasible, brachytherapy was applied. For this 
purpose, a 
137Cesium application of 17.5 Gy to point A was 
given and this was repeated after one week up to a total dose 
of 35 Gy. If brachytherapy was not feasible or inappropriate in 
case of tumour extension into parametrium or lymph nodes, 
patients received an additional external boost over 3 weeks 
up to a total dose of 70.2 Gy, with standard fractionation.
Chemotherapy: Seventy­five patients received chemo­
therapy, including 3 cycles of carboplatin and 5­fluorouracil 
(5­FU). Carboplatin, 300 mg/m
2, was dissolved in 250 ml 5% 
glucose and given over 30 minutes intravenously (i.v.) on 
day 1. 5­FU, 600 mg/m
2, was dissolved in 2 liter normal saline 
and administered continuously i.v. on days 2­5. Cycles were 
repeated after 28 days for a total of 3 during the first, fifth and 
ninth week of treatment. Dose modifications only concerned 
carboplatin. Cycle 3 was given together with the external 
boost or in sequence to the second application of 
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brachytherapy. 
Surgery: Until 1994, in Groningen, all patients who were fea­
sible for surgery underwent an additional hysterectomy [28]. 
This comprised an extrafascial hysterectomy and removal of 
enlarged lymph nodes. In patients in whom a radical hysterec­
tomy was not deemed feasible, no further action was taken. 
3. Follow-up 
Patients were followed by the radiation­oncologist alterna­
ting with the gynecologic­oncologist at regular intervals for 
10 years. Late treatment­related side effects were evaluated 
during each visit by structured questioning daily life problems 
in physical and psychosexual functioning and with special at­
tention to urinary tract and intestinal symptoms. A physical 
examination was performed for evaluating tumour recurrence 
and treatment­related side effects. 
4. Scoring of radiation-induced side effects
For the purpose of this study, side effects were scored retro­
spectively by reviewing the medical charts for late toxicity us­
ing standardised checklists. Treatment and follow­up of these 
patients has been done by 2 dedicated radiation oncologists 
with special expertise in gynecological oncology, and who 
were and are both very keen on assessing reporting toxic­
ity. For this purpose, they used a well structured questioning 
methodology focusing on bladder and bowel toxicity. The first 
checklist was based on the CTCAE v3.0 and the second on the 
“late radiation morbidity scoring scheme” of the RTOG/EORTC 
[18,21], focusing on bladder­ and intestinal toxicity. The RTOG/
EORTC scoring system is a generally accepted method to as­
sess radiation­induced side effects in gynecologic oncology. 
However, the main limitation of this scoring system is that 
it enables just one composed scale for urologic and one for 
intestinal side effects. The CTCAE v.3.0 enables scoring in dif­
ferent kinds of gastrointestinal and urologic side effects and 
provides a more comprehensive way of scoring radiation­
induced side effects. For this reason, we used the CTCAE v3.0 
to investigate the impact of these side effects on HRQoL.
5. Health-related quality of life
A total number of 45 out of 114 patients (39%) still alive were 
asked to fill out a HRQoL questionnaire. Those who did not re­
spond were contacted by telephone. Eventually, 34 out of 45 
survivors (76%) responded. Three of the non­responders had 
a second malignancy that was treated with palliative chemo­
therapy. One patient refused to participate and seven patients 
did not respond for unknown reasons. Of the responders, 16 
patients underwent an additional hysterectomy. 
For the evaluation of HRQoL, the EORTC core questionnaire 
(QLQ­C30 ver. 3.0) was used [18,24,25]. The EORTC QLQ­C30 
is a cancer­specific quality of life questionnaire developed for 
repeated assessments within clinical trials. It is developed in 
a cross­cultural setting and has been found valid and reliable 
for quality of life assessments in various cancer populations. It 
contains five functional scales (physical, cognitive, emotional, 
social and role), a global quality of life scale, three symptom 
scales (pain, fatigue and nausea/vomiting) and six single items 
(dyspnea, insomnia, loss of appetite, constipation, diarrhea 
and financial difficulties). 
6. Statistics 
For the analysis of late radiation­induced side effects, the in­
cidences of grade ≥ 2 late side effects during the first 10 years 
were estimated. Univariate and multivariate logistic regres­
sion analyses were performed to study the additional risk of 
concurrent chemoradiation reference to radiotherapy alone. 
Associations were expressed as odds ratios (OR) along with 
95% confidence intervals (95% CI). An OR can be interpreted 
as a relative risk. First, univariate analyses were carried out 
to calculate the unadjusted association between treatment 
modality and side effects. In addition, multivariate analyses 
were performed to adjust for the imbalance between the two 
treatment groups with regard to age and follow­up time. The 
following variables were entered in the model: age, chemo­
therapy (yes or no), surgery (yes or no), FIGO stage (stage I­II 
vs. III) and boost technique (external beam versus brachyther­
apy). All results were considered statistically significant when 
p<0.05.
All scales of the EORTC QLQ­C30 were linearly converted to 
a 0 to 100 scale. For the functional and global health status/
quality of life scales, higher scores represent a better level of 
functioning. For symptom scales, higher scores represent a 
greater degree of symptoms. 
To analyze the association between the late treatment­
related morbidity and HRQoL, the general linear model (GLM)­
multivariate analysis of variance (MANOVA) was used. The 
GLM­MANOVA approach can be used to test the hypothesis of 
a significant association between a set of interrelated depen­
dent variables, e.g., the quality of life scales, and one or more 
grouping variables. This method was preferred over analysis 
of each quality of life domain separately, because it also takes 
into account the correlation among the individual quality of 
life scales. This multivariate approach also protects against 
type I errors. In the present study, MANOVA was performed in 
two steps. First, to investigate the association of a given prog­
nostic factor with HRQoL, an overall analysis was performed 
to establish whether the prognostic factors were significantly 
associated with any of the HRQoL domains. In case of a sig­Treatment-related morbidity and QoL in cervical carcinoma
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nificant association between a late toxicity grading and all 
quality of life domains taken together, a second analysis was 
performed to investigate the association between that factor 
and each quality of life domain separately. 
In the current study, the mean scores of the HRQoL scales 
observed among patients with a grade 2­4 were compared to 
the scores observed among patients with a grade 0­1 scoring. 
The clinical relevance of the differences in the mean scores of 
the HRQoL scales between groups was classified by calculat­
ing the effect size using Cohen’s D coefficient. An effect size of 
≥ 0.20­0.49 is generally considered small, ≥ 0.50­0.79 as mod­
erate and ≥ 0.8 as large.
RESULTS
1. Patients
The pre­treatment characteristics of the study population 
are listed in Table 1. The two groups were well balanced with 
regard to most patient characteristics except for age. The 
mean age was 59 years in the RT group and 47 years in the 
CRT group (p<0.001). Brachytherapy was given to 23 of the 
patients in the radiotherapy group and to 38 patients in the 
combined group. Fifty­four percent of all patients underwent 
an additional (radical) hysterectomy (49% in the RT group, 
56% in the CRT group). Until 1994 all patients underwent an 
additional hysterectomy if patients were feasible for surgery 
[28]. The mean follow­up was 4.0 years (range, 0.4 to 15.8 
years) in the RT group and 6.8 years (range, 0.4 to 15.8 years) 
in the CRT group (p=0.002), respectively. 
2. Incidence of late radiation-induced side effects
The total median follow­up time for the whole group inves­
tigated was 5.8 years, and was 6.8 years among the patient 
who received CRT compared to 4.0 years among those who 
received RT alone (p=0.002). With the EORTC/RTOG scoring 
system, the highest incidence of grade ≥ 2 late side effects 
was found for bladder toxicity (33%), while grade ≥ 2 late small 
and large intestinal toxicity was found in 6% of the patients. 
Only 1.8% had grade 3­4 toxicity for both bladder and bowel. 
Using the CTCAE v.3.0 scoring system, the highest incidence 
of grade ≥ 2 was observed for cystitis (39%). The CTCAE v.3.0 
system provided a more detailed description of the differ­
ent toxicities than the EORTC/RTOG system did with slightly 
higher incidence rates (Table 2). Using univariate and multi­
variate logistic regression analysis, no significant differences 
Table 1. Patients characteristics
Variable Radiotherapy (n=39) Chemoradiation (n=75)
Age (yr) 59 (30-78) 47  (28-73) <0.001
Follow-up (yr) 4.0   (0.4-15.8) 6.8    (0.2-15.2)
Morphology
Squamous cell  30 (77) 60 (80) NS
Adeno 3 (8) 5 (6) NS
Neuro-endocrine 0 (0) 2 (3) NS
Smallcell squamous 4 (10) 5 (6) NS
Adenosquamous 2 (5) 3 (4) NS
FIGO-stage
IB 3 (8) 7 (9) NS
IIA 5 (3) 5 (7) NS
IIB 24 (62) 45 (60) NS
IIIA 2 (5) 1 (1) NS
IIIB 5 (13) 17 (23) NS
Salvage hysterectomy 19 (49) 43 (56) NS
Boost-technique
External beam 16 (41) 25 (33) NS
Brachytherapy 23 (59) 38 (51) NS
Combination 0 (0) 11 (15) NS
Values are presented as mean (range) or number (%). 
NS, not significant.Maaike J. Berveling, et al.
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in baseline characteristics between the two treatment groups 
were observed with regard to the incidence of grade ≥ 2 side 
effects for any of the toxicity scales (Table 2). 
The incidences of grade 3­4 late side effects were low (Table 2). 
No significant differences between the two treatment groups 
were observed. Because of the low number of events, multi­
variate logistic regression analysis was not feasible and there­
fore omitted.
3. Association between late side effects and HRQoL
In the first step of the GLM­MANOVA, the association be­
tween the CTCAE v3.0 toxicity scales and HRQoL was investi­
gated. In this analysis, a linear combination of the functioning 
scales, the global QoL scale and general symptom scales as­
sessed with all EORTC QLQ­C30 scales used as the dependent 
variable. Ileus and fecal incontinence were excluded from the 
analysis, because of the low number of events. The toxicity 
scales cystitis, urinary incontinence and enteritis were signifi­
cantly associated with HRQoL (Table 3). 
In addition, for the scales that significantly affected all 
HRQoL together, we investigated the impact of late radiation­
induced morbidity on the individual HRQoL­scales. For cystitis, 
large effect were observed on different HRQoL scales, includ­
ing global quality of life, physical functioning, role functioning, 
emotional functioning, social functioning and fatigue (Table 
4). For urine incontinence, large effects were observed on 
global quality of life, physical functioning, role functioning, 
and social functioning (Table 4). 
Enteritis had a significant effect on physical functioning, 
emotional functioning and insomnia (Table 5).
DISCUSSION
In this retrospective study, we examined the incidence of 
late radiation­induced side effects among patients curatively 
treated for cervical cancer that were followed for a long pe­
riod of time. The results revealed that grade 2 or higher late 
radiation­induced side effects occurred in a relatively large 
proportion of patients of which the majority suffered from uri­
nary tract toxicities. However, the incidence of severe, grade 
3­4 side effects remained within reasonable limits, i.e. less 
than 2% for most toxicity scales up to 9.6% for urinary inconti­
nence. Similar results were found by Lajer et al. [4] among 177 
Table 2. Cumulative incidence for toxicity grade 2 or higher and grade 3 or higher treatment-related morbidity 
Treatment-related toxicity
Incidence (%) Logistic regression analysis
All patients 
(n=114)
Radiotherapy 
(n=39)
Concurrent 
chemoradiation 
(n=75)
Univariate analysis Multivariate analysis
 Unadjusted OR 
(95% CI)
p-value Adjusted OR 
(95% CI)
p-value
≥ grade 2 ≥ grade 3 ≥ grade 2 ≥ grade 3 ≥ grade 2 ≥ grade 3
RTOG/EORTC
Bladder  33 1.8 36 2.6 32 1.3 0.84 (0.37-1.89) 0.676 0.54 (0.22-1.34) 0.182
Small and large intestine  6 1.8 5 0 9 2.8 1.90 (0.38-9.64) 0.436 1.85 (0.35-9.85) 0.473
CTCAE v 3.0
Cystitis 39 0.9 44 2.6 37 0 0.81 (0.37-1.81) 0.611 0.51 (0.21-1.26) 0.144
Urinary incontinence 22 9.6 21 12.8 23 8.0 0.98 (0.38-2.48) 0.965 0.75 (0.28-2.04) 0.574
Enteritis  27 1.8 21 0 31 2.7 1.97 (0.78-4.95) 0.149 1.95 (0.75-5.09) 0.174
Diarrhoea  8 0 5 0 9 0 2.22 (0.45-11.1) 0.329 2.56 (0.49-13.4) 0.265
Ileus 9 1.8 10 0 8 2.7 0.88 (0.25-3.31) 0.877 0.78 (0.20-3.06) 0.718
Proctitis 6 0.9 5 2.6 7 0 1.33 (0.25-7.19) 0.744 0.67 (0.11-4.23) 0.672
Faeces incontinence 2 0 3 0 1 0 0.51 (0.03-8.46) 0.642 0.29 (0.02-5.54) 0.41
None of the differences were statistically significant. The adjusted OR refers to the results of the multivariate analysis on the effect of treatment 
modality corrected for age and follow-up time.
Table 3. Results of the general linear model multivariate analysis for 
variance testing the effect of the CTCAE v3.0 toxicity scales and on all 
health-related quality of life domains
Independent variables Wilks' Lambda p-value
Cystitis (grade 0-2 vs. 3-4) 0.20 0.02
Urine incontinence (grade 0-2 vs. 3-4) 0.22 0.02
Enteritis (grade 0-2 vs. 3-4) 0.23 0.03
Diarrhoea (grade 0-2 vs. 3-4) 0.37 NS
Proctitis (grade 0-2 vs. 3-4) 0.42 NS
NS, not significant.Treatment-related morbidity and QoL in cervical carcinoma
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patients who received radiotherapy alone for cervical carci­
noma. In their study, the incidence of grade 1, 2 and 3 toxicity 
together varied from 25 to 62%. The amount of grade 2 toxic­
ity in their study was 2­32% for grade 1­2 and only 0­4% for 
grade 3 [4]. 
In the current study, the incidence of urine incontinence was 
22% for all grade 2­4 and 9.8% for grade 3­4, which was higher 
than expected. However, the definition of urine incontinence 
according to the CTCAE v3.0 scoring system does not allow 
for a distinction between urine incontinence resulting from 
Table 4. Results of the general linear model multivariate analysis of variance testing the effect of the urinary tract CTCAE v3.0 toxicity scales on 
the individual EORTC QLQ-C30 domains
Quality of life scales
(n=34)
Cystitis Urine incontinence
Grade 0-1 Grade 2-4
Cohen's D p-value 
Grade 0-1 Grade 2-4
Cohen's D p-value 
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Global quality of life 89 (9.8) 58 (23.1) 1.79* <0.001 84 (18.3) 65 (24.8) 0.87* 0.028
Physical functioning 88 (16.9) 70 (17.2) 1.06* 0.011 89 (15.6) 67 (17.1) 1.33* 0.002
Role functioning 91 (19.2) 52 (27.3) 1.74* <0.001 88 (22.8) 53 (28.1) 1.37* 0.001
Emotional functioning 94 (7.6) 80 (18.0) 1.67* 0.006 92 (10.4) 84 (19.0) 0.53 NS
Cognitive functioning 94 (11.6) 80 (25.6) 1.38 NS 91 (17.9) 83 (20.8) 0.41 NS
Social functioning 96 (10.8) 73 (28.2) 1.08* 0.003 95 (11.2) 73 (30.6) 1.50* 0.010
Fatigue 12 (17.7) 43 (32.5) 1.13* 0.003 18 (22.6) 34 (35.3) 0.54 NS
Nausea and vomiting 1 (3.9) 6 (19.5) 0.60 NS  2 ( 5.3)  5 (11.2) 0.35 NS
Dyspnoea  6 (12.8) 12 (16.8) 0.40
† 0.050  7 (14.0) 10 (16.1) 0.20 NS
Insomnia  7 (18.3) 46 (30.8) 1.50 NS 18 (30.2) 30 (29.2) 0.41 NS
Appetite loss 0  9 (21.6) 0.58 NS  2 (7.6)  7 (21.1) 0.31 NS
Constipation 0 3 (10.1) 0.42 NS 0  3 (10.5) 0.39 NS
Financial difficulties 0 21 (34.2) 0.87 NS  4 (15.3) 17 (32.4) 0.52 NS
NS, not significant.
*Cohen's D=large effect (Cohen’s D > 0.8). 
†Cohen's D=small effect (Cohen’s D 0.2-0.5).
Table 5. Results of the general linear model multivariate analysis of variance testing the effect of the CTCAE v3.0 toxicity scales of the rectum on 
the individual EORTC QLQ-C30 domains
Quality of life scales
(n=34)
Enteritis
Grade 0-1 Grade 2-4
Cohen's D p-value 
Mean (SD) Mean (SD)
Global quality of life 81 (21.5) 67 (16.7) 0.73 NS
Physical functioning 85 (18.3) 67 (13.3) 1.15* 0.047
Role functioning 79 (29.2) 60 (27.9) 0.67 NS
Emotional functioning 92 (11.3) 77 (20.7) 0.89* 0.028
Cognitive functioning 90 (17.0) 80 (27.4) 0.44 NS
Social functioning 88 (21.1) 90 (14.9) 0.11 NS
Fatigue 19 (25.7) 42 (34.6) 0.75 NS
Nausea and vomiting 2 ( 7.5) 7 (9.1) 0.62 NS
Dyspnoea  7 (13.8) 13 (18.3) 0.37 NS
Insomnia 14 (27.7) 47 (18.3) 1.40* 0.018
Appetite loss  4 (14.9) 0 0.38 NS
Constipation 0  7 (14.9) 0.66
† 0.026
Financial difficulties  10 (25.0) 0 0.57 NS
NS, not significant.
*Cohen’s D=large effect (Cohen’s D > 0.8). 
†Cohen’s D=small effect (Cohen’s D 0.2-0.5).Maaike J. Berveling, et al.
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cancer treatment or other causes, e.g., surgery. In this respect, 
it should be noted that the overall incidence of urine inconti­
nence in healthy elderly women in the Netherlands increases 
with age (Central Bureau for Statistics, the Netherlands, CBS), 
e.g., Kok et al. [29] reported on a cohort study among Dutch 
women of ≥ 60 years of age and found a prevalence of urine 
incontinence of 23.5%. The mean age of the current study 
population was 53 years at the time of treatment, and most of 
the women were post­menopausal, which means that the ob­
served incidence of 22% will only be partly due to the cancer 
treatment. 
Of our study population, 54% underwent an additional hys­
terectomy. The general policy at our hospital since 1994 is to 
perform an additional hysterectomy approximately 10 weeks 
after completion of radiation, if a biopsy proved to be positive 
for residual tumour. When a radical resection is considered 
possible by the gynecologist, a gynecologic examination 
under general anesthesia 8­10 weeks after completion of 
treatment is planned. In case a central biopsy proved to be 
tumour negative, no additional surgery is performed [28]. The 
high incidence of bladder toxicity may partly be due to the 
performed surgery in this group. In the CTCAE v3.0 overall tox­
icity is scored and not differentiated according to the type of 
treatment. For the currently treated patients, the incidence of 
bladder toxicity may be increased because of the biopsy posi­
tive additional surgery. 
Although, we observed some trends towards more late 
radiation­induced side effects among patients treated with 
chemoradiation, e.g., for diarrhea and enteritis (CTCAE v3.0) 
and for small and large intestinal toxicities (EORTC/RTOG) 
These differences were not statistically significant, even after 
correction for two potential confounding factors (age and 
follow­up). Retrospective studies showed that the incidence 
of late bowel toxicity such as increased frequency, abdominal 
pain, diarrhea, rectal blood or mucus loss, and rectal discom­
fort increased dramatically with doses higher than 50­55 Gy 
[30]. However, with modern treatment techniques, the risk of 
severe late side effects is 5% or less [12,30]. Although in most 
randomized studies, acute toxicity rates were significantly 
higher with chemoradiation, this does not seem to result in 
more late side effects. These results are similar to those re­
ported by Eiffel et al. [12]. 
The most recently adapted toxicity scoring system, the CT­
CAE v3.0, includes the definitions of a large set toxicity items 
for both acute and late side effects and does not only take 
into account toxicity induced by radiotherapy but also side 
effects induced by other treatment modalities such as surgery 
and chemotherapy [18,24]. Although the CTCAE v3.0 is cur­
rently the most specific and frequently used grading system 
for treatment­related side effects in clinical trials, most papers 
on radiotherapy will use the less specific RTOG/EORTC system. 
Since 2006 there is a specific module for cervical carcinoma 
patients (CX 24). It specifies the problems that could exist af­
ter radiotherapy treatment e.g., bladder, intestine and sexual 
functioning. In the current study, toxicity was graded accord­
ing to both CTCAE v3.0 and RTOG/EORTC systems, because 
the CX 24 was not available. The results of this study clearly in­
dicate that mutual comparison of late radiation­induced side 
effects between studies that used different toxicity grading 
systems is severely hampered by these discrepancies. 
The female pelvis contains several critical organs, and there­
fore a variety of complications may occur in patients treated 
with radiation therapy to this area. Severe complications may 
overshadow the more mild complications. Multiplicity of ther­
apeutic approaches requires scoring systems that considers all 
types of side effects, but it has to specify the type of different 
complaints. Moreover, different kinds of late morbidity may 
have different impact. For instance, bowel obstruction can be 
treated and thus may be reversible, while urine incontinence 
may continue to increase throughout the remaining life pe­
riod. In the current study, we found that cystitis, urine inconti­
nence and enteritis had a severely/markedly negative impact 
on various HRQoL domains. It should be stressed that even 
though the majority of patients had grade 2 side effects or 
less, both general as well as the more specific dimensions of 
HRQoL were affected. The proportion of patients with grade 
3­4 side effects was low and therefore, the impact of these 
higher grades of toxicity on HRQoL remains to be determined. 
Nevertheless, these results indicate that although physicians 
generally consider grade 2 side effects as mild and accept­
able, from the patient’s perspective the impact of these side 
effects may be impressive. Some “mild” side effects may have 
more effect than “severe” side effects, e.g., depending on their 
duration and potential for reversibility [4]. Similar results were 
found by other investigators [31]. 
The results of the present study clearly indicate that radia­
tion­induced morbidity has a significant impact on various 
HRQoL domains. Especially bladder toxicity is a important 
finding, because late bladder toxicity increases in time [26]. 
Since survival in patients with cervical carcinoma increases, 
very late bladder toxicity may become a problem for these 
women.
In this study, the frequency of bladder toxicity may be high 
due to the use of older radiation techniques. The external 
beam radiation is planned with a box technique instead of 
CT planning nowadays. In reports obtained with intensity 
modulated radiotherapy in cervical cancer that have been 
published, only acute and early late side effects have been re­Treatment-related morbidity and QoL in cervical carcinoma
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ported thus far [32]. 
A more important factor might be the brachytherapy tech­
nique. Dose prescription in point A gives high doses in rectum 
and bladder. Modern brachytherapy techniques with MRI 
planning can reduce these dose and give a more detailed 
dose distribution in organs at risk [33]. 
Although these developments in treatment techniques will 
reduce bladder­ and rectal late treatment related morbid­
ity, the impact on HRQoL is evident. Therefore, scoring late 
treatment related morbidity must be scored consequently in 
follow­up.
The present study with long term follow­up revealed a con­
si  de  rable proportion of patients with late grade 2 urinary and 
gastro­intestinal tract sequelae. These side effects have a ma­
jor impact on HRQoL despite the occurrence of grade 3­4 toxi­
ci  ty in only a minority of patients. New radiation techniques 
aiming at reduction of these side effects may carry less toxicity 
with a positive impact on HRQoL. 
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